Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Teriparatide treatment complicated by malignant myeloma.

Literature DB >> 22767690

Teriparatide treatment complicated by malignant myeloma.

Anna-Mari Koski¹, Anu Sikiö, Terje Forslund.

Abstract

Recombinant human parathyroid hormone (1-34) (rhPTH 1-34), teriparatide (Forsteo in Europe), is a new compound that has been introduced and shown to be successful in the treatment of osteoporosis. The mechanisms of action include a pulsative influence on the RANKL/OPG system resulting in osteoblast activation and increased bone formation by teriparatide. In malignant myeloma there is an imbalance between osteoclast and osteoblast activity with involvement of the RANKL/OPG system among others. We report a case with monoclonal gammopathy of uncertain significance (MGUS) who developed malignant myeloma after teriparatide treatment and we suggest that in addition to malignant myeloma and smouldering myeloma, MGUS should also be considered contraindicated for teriparatide treatment.

Entities: Chemical Disease Gene Species

Mesh：

Substances：
Teriparatide

Year: 2010 PMID： 22767690 PMCID： PMC3027506 DOI： 10.1136/bcr.01.2010.2681

Source DB: PubMed Journal: BMJ Case Rep ISSN： 1757-790X

11 in total

Review 1. Clinical practice. Monoclonal gammopathy of undetermined significance.

Authors: Joan Bladé
Journal: N Engl J Med Date: 2006-12-28 Impact factor: 91.245

2. Receptors for the carboxyl-terminal region of pth(1-84) are highly expressed in osteocytic cells.

Authors: P Divieti; N Inomata; K Chapin; R Singh; H Jüppner; F R Bringhurst
Journal: Endocrinology Date: 2001-02 Impact factor: 4.736

Review 3. Secretion of parathyroid hormone-related peptide in patients with multiple myeloma.

Authors: J Beaudreuil; M Cohen-Solal; M X Doré; M C Vernejoul; T Bardin; N Celton; V Giraudeaux; D Kuntz
Journal: Rev Rhum Engl Ed Date: 1996 Jul-Sep

Review 4. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

Authors: Anthony B Hodsman; Douglas C Bauer; David W Dempster; Larry Dian; David A Hanley; Steven T Harris; David L Kendler; Michael R McClung; Paul D Miller; Wojciech P Olszynski; Eric Orwoll; Chui Kin Yuen
Journal: Endocr Rev Date: 2005-03-15 Impact factor: 19.871

5. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

Authors: R M Neer; C D Arnaud; J R Zanchetta; R Prince; G A Gaich; J Y Reginster; A B Hodsman; E F Eriksen; S Ish-Shalom; H K Genant; O Wang; B H Mitlak
Journal: N Engl J Med Date: 2001-05-10 Impact factor: 91.245

6. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.

Authors: M Ocqueteau; A Orfao; J Almeida; J Bladé; M González; R García-Sanz; C López-Berges; M J Moro; J Hernández; L Escribano; D Caballero; M Rozman; J F San Miguel
Journal: Am J Pathol Date: 1998-06 Impact factor: 4.307

7. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).

Authors: Eric C Buxton; Wei Yao; Nancy E Lane
Journal: J Clin Endocrinol Metab Date: 2004-07 Impact factor: 5.958

8. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety.

Authors: John L Vahle; Masahiko Sato; Gerald G Long; Jamie K Young; Paul C Francis; Jeffery A Engelhardt; Michael S Westmore; Yanfei Linda; James B Nold
Journal: Toxicol Pathol Date: 2002 May-Jun Impact factor: 1.902

9. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial.

Authors: J Reeve; P J Meunier; J A Parsons; M Bernat; O L Bijvoet; P Courpron; C Edouard; L Klenerman; R M Neer; J C Renier; D Slovik; F J Vismans; J T Potts
Journal: Br Med J Date: 1980-06-07

Teriparatide treatment complicated by malignant myeloma.

Review 1. Clinical practice. Monoclonal gammopathy of undetermined significance.

2. Receptors for the carboxyl-terminal region of pth(1-84) are highly expressed in osteocytic cells.

Review 3. Secretion of parathyroid hormone-related peptide in patients with multiple myeloma.

Review 4. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

5. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

6. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.

7. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).

8. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety.

9. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial.

10. Malignant myeloma in a patient after treatment for osteoporosis with teriparatide; a rare coincidence.

1. Mining MEDLINE for the treatment of osteoporosis.

2. Coexistent osteoporosis and multiple myeloma: when to investigate further in osteoporosis.

3. Atypical femur fracture in a woman with osteogenesis imperfecta and multiple myeloma.

Review 4. Therapeutic Treatments for Osteoporosis-Which Combination of Pills Is the Best among the Bad?

Review 5. Myeloma Bone Disease: A Comprehensive Review.